Hepatitis E virus (HEV) was first identified in 1980 as a new hepatitis pathogen found primarily in Asia, Africa and South America. Although the clinical presentation is similar to HAV, HEV is more severe; HEV results in a 1-2% death rate and is often associated with fulminant hepatic failure in pregnant women and an increased risk of mortality in the third trimester. HEV antibody responses peak at about one month after initial infection. Antiviral IgM is detected in >90% of patients and persists for 3 months. Anti-HEV IgM is also a well-established marker of recent infection and is the most convenient one for diagnosis.

  • 3rd Generation, double-antigen based test to increase the sensitivity in early detection
  • Requires only 20 µL of specimen
  • Use serum, plasma or whole blood
  • Results available within 15 min to allow prompt action to be taken at the point of care
  • Performance validated with BBI low titre panel and Chinese FDA HIV Ab Panel
  • Individually sealed foil pouches containing:
    • One cassette device
    • One desiccant
  • 20 uL capillary tubes
  • Sample diluent (REF SB-R0011, 5 mL/bottle)
  • Package insert (instruction for use)

Catalog #

R0011C

Product

HIV 1/2 Ab Plus Combo Rapid Test

Quantity

30/kit

Specimen

S, P & WB

Other Products You Might Be Interested In

Catalog #

R0042C
R0042C

Product

HIV 1/2 Ab HBsAg Combo Rapid Test
TB IgG/IgM Combo Rapid Test CE

Quantity

30/kit
30/kit

Specimen

S, P & WB
S, P & WB